Analysts Set KORU Medical Systems, Inc. (NASDAQ:KRMD) Price Target at $7.25

KORU Medical Systems, Inc. (NASDAQ:KRMD) has received an average rating of “Moderate Buy” from the five ratings firms that are covering the company, MarketBeat reports. One analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. The average twelve-month price objective among brokerages that have issued ratings on the stock in the last year is $7.25.

A number of equities research analysts have recently weighed in on KRMD shares. Wall Street Zen raised shares of KORU Medical Systems from a “hold” rating to a “buy” rating in a research note on Saturday, July 4th. Weiss Ratings raised KORU Medical Systems from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, June 24th.

Insider Buying and Selling at KORU Medical Systems

In other news, insider Adam R. Kalbermatten purchased 12,500 shares of KORU Medical Systems stock in a transaction that occurred on Thursday, June 11th. The shares were bought at an average cost of $3.94 per share, with a total value of $49,250.00. Following the completion of the purchase, the insider directly owned 312,500 shares in the company, valued at approximately $1,231,250. This trade represents a 4.17% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders purchased 28,000 shares of company stock worth $109,430 in the last 90 days. Insiders own 18.50% of the company’s stock.

Institutional Trading of KORU Medical Systems

Hedge funds have recently modified their holdings of the business. Bank of America Corp DE increased its stake in shares of KORU Medical Systems by 36.0% in the 1st quarter. Bank of America Corp DE now owns 37,971 shares of the company’s stock worth $164,000 after acquiring an additional 10,045 shares in the last quarter. Royal Bank of Canada boosted its stake in KORU Medical Systems by 77.3% during the first quarter. Royal Bank of Canada now owns 235,804 shares of the company’s stock worth $1,019,000 after acquiring an additional 102,800 shares in the last quarter. Vivaldi Capital Management LP grew its holdings in KORU Medical Systems by 51.6% in the first quarter. Vivaldi Capital Management LP now owns 29,885 shares of the company’s stock worth $129,000 after purchasing an additional 10,172 shares during the period. Renaissance Technologies LLC purchased a new stake in KORU Medical Systems in the first quarter worth about $198,000. Finally, Arrowstreet Capital Limited Partnership bought a new position in shares of KORU Medical Systems during the first quarter valued at approximately $79,000. Institutional investors own 58.60% of the company’s stock.

KORU Medical Systems Price Performance

KORU Medical Systems stock traded down $0.15 during mid-day trading on Friday, reaching $4.28. 104,706 shares of the company traded hands, compared to its average volume of 153,207. KORU Medical Systems has a 52-week low of $2.91 and a 52-week high of $6.61. The firm has a market capitalization of $196.58 million, a price-to-earnings ratio of -85.60 and a beta of 0.41. The firm’s 50 day moving average price is $4.12 and its 200 day moving average price is $4.63.

KORU Medical Systems Company Profile

KORU Medical Systems, Inc develops and manufactures medical devices and supplies in the United States and internationally. It offers the freedom infusion systems to deliver life-saving therapies to patients with chronic illnesses, such as primary immunodeficiency diseases, chronic inflammatory demyelinating polyneuropathy, and paroxysmal nocturnal hemoglobinuria. Its products include the FREEDOM60 syringe infusion system, the FreedomEdge syringe driver, HIgH-Flo subcutaneous safety needle sets, and precision flow rate tubing products.